Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT06935734

Robotic Colonoscopy Using the Triton 4.0 System in Adults for Screening, Surveillance, and Diagnosis of Lower Gastrointestinal Conditions

This study is a prospective, single-arm, non-randomized, single site first-in-human study and will be conducted in two phases, where Phase A will serve to evaluate the safety of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies, and Phase B will evaluate the safety and efficacy of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥ 22 years
  • Adults indicated for elective screening, surveillance or diagnostic colonoscopy
  • Subject is willing and able to provide written informed consent prior to receiving any non-standard of care Clinical Investigation Plan specific procedures
  • Subject is willing and able to comply with all Clinical Investigation Plan required preparation and follow- up visits -

Exclusion criteria

Initial Screening / Pre-Operative:

  • Any medical or physical condition/limitation that would contraindicate a conventional colonoscopy. This assessment will be made by the investigator.
  • Any active implantable medical devices (e.g., pacemakers, defibrillators)
  • Previous failed colonoscopy (except for inadequate bowel preparation)
  • BMI > 45 kg/m2
  • Pregnant participants, women of reproductive potential (pre-menopausal and/or no history of hysterectomy), confirmed by a positive pregnancy test (serum).
  • Surgically altered colonic anatomy
  • History of colorectal cancer, inflammatory bowel disease, polyposis syndrome, hereditary nonpolyposis colorectal cancer (Lynch) syndrome, sclerosing encapsulating peritonitis, active diverticulitis in last 6 months or toxic megacolon
  • Lower gastrointestinal bleeding within 28 days prior to the colonoscopy day
  • Known bleeding tendency such as hemophilia or coagulation factor deficiencies
  • Patient receiving antiplatelet or anticoagulation therapy apart from low-dose aspirin
  • Known colonic stricture
  • Known risk factors for abdominal adhesions such as history of complex abdominal or pelvis surgical procedures, based on investigator assessment
  • Known abdominal wall hernias
  • History of radiotherapy to the abdomen or pelvis
  • History of mesenteric ischemia
  • Known coronary ischemia or cardiovascular stroke within 3 months prior to the colonoscopy procedure
  • Contraindication to the proposed sedation / anesthesia
  • Received any investigational medicine or treatment within 28 days prior to the colonoscopy procedure
  • Received or planning to receive any other endoscopic procedure within 4 weeks prior and 2 weeks after the colonoscopy procedure
  • Participation in any concurrent clinical trial that may impact the results of this study

Intra-Operative Exclusion Criteria:

  • Inadequate Bowel Preparation, Boston Bowel Prep Scale Score (after cleansing) < 2 in any section
  • Failed conventional colonoscopy or polypectomy/biopsy performed during the conventional colonoscopy procedure in Phase A
  • Any presenting condition discovered intraoperatively that in the opinion of the investigator would make participating in this study not in the participant's/patient's best interest. For example, presence of a stricture or tight sigmoid that would make passing an overtube risky for the patient
  • Any condition, in the opinion of the Investigator, that is unstable and could jeopardize the safety of the subject and their compliance in the study

Treatment and study plan

Diagnostic Colonoscopy

Diagnostic Test

Phase A will serve to evaluate the safety of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies, and Phase B will evaluate the safety and efficacy of the Triton 4.0 System to perform screening, surveillance and diagnostic colonoscopies.

Primary outcomes

  1. Safety Endpoint - Incidence of Major Adverse Events Within 48 Hours

    Time frame: 48 hours

    Absence of Major Adverse Events (MAEs) within 48 hours of the procedure. MAEs are defined as any of the following:

    • Device-related death within 48 hours
    • Perforation within 48 hours
    • Intraprocedural bleeding preventing completion of the procedure
    • Delayed bleeding within 48 hours accompanied by pre-defined symptoms and confirmed by a hemoglobin drop of >2 g, leading to admission to the hospital, prolongation of hospital stay, or another procedure requiring sedation/anesthesia.

    Unit of Measure: Number of participants with at least one Major Adverse Event

  2. Efficacy Endpoint - Successful Completion of Colonoscopy

    Time frame: During procedure

    Completion of colonoscopy defined by both: (a) successful cecal intubation (clinically acceptable access and visualization of the cecum), and (b) successful withdrawal (clinically acceptable diagnostic and therapeutic access of the entire colon tract).

Secondary outcomes

  1. Time to Cecum

    Time frame: During procedure

    Time from scope insertion to successful cecal intubation. Unit of Measure: Minutes

  2. Need for Repositioning

    Time frame: During procedure

    Number of times a participant was repositioned to facilitate scope advancement. Unit of Measure: Number of repositioning events

  3. Polypectomy Success

    Time frame: During procedure

    If applicable, indicates whether at least one polyp was successfully removed using standard polypectomy tools during the procedure. This outcome is evaluated per participant and applies only to Phase B (robotic procedures).

    Unit of Measure: Categorical - Yes / No / Partial (i.e., at least one polyp removed, but not all targeted polyps).

  4. NASA Task Load Index (NASA-TLX)

    Time frame: Post-procedure

    Physician's subjective workload assessment using the NASA Task Load Index (NASA-TLX), a validated tool consisting of six subscales: Mental Demand, Physical Demand, Temporal Demand, Performance, Effort, and Frustration. Each subscale is scored from 0 to 100 in increments of 5. Higher scores indicate greater perceived workload.

    Unit of Measure: Composite score (0-100)

  5. Mucosal Injury Score

    Time frame: During procedure

    Mucosal injury graded using a 5-point ordinal scale based on injury severity: 1 = Erythema/ Bruising, 2 = Mucosal break <5mm in length, 3 = Mucosal break >5mm in length, 4 = Mucosal Injury (non-full thickness), 5 = Full thickness injury. Outcome is reported per subject. Only applicable to Phase B (robotic procedures).

    Unit of Measure: Score (1-5); higher scores indicate more severe injury

  6. Delayed Bleeding (14 Days)

    Time frame: 14 days

    Number of participants with delayed bleeding within 14 days confirmed by pre-determined symptoms and hemoglobin drop of >2 g/dL.

    Unit of Measure: Number of participants

  7. Delayed Perforation (14 Days)

    Time frame: 14 days

    Number of participants with delayed perforation identified within 14 days post-procedure.

    Unit of Measure: Number of participants

  8. Adenoma Detection Rate (ADR)

    Time frame: During procedure

    Proportion of participants in whom at least one adenomatous polyp is detected during the robotic colonoscopy procedure. Applicable to Phase B (robotic procedures) only.

    Unit of Measure: Percentage of participants with ≥1 adenoma detected

Study contacts

Contact information is provided by the study sponsor or research team.

Aishwarya Gosai

CONTACT

[email protected]

(949) 394 8073

Sponsors and collaborators

Lead sponsor

Neptune Medical

Industry

Collaborators

  • H-T. Centrum Medyczne Sp. z o.o. sp. k
  • KCRI

Registry information

Official study title

Colonoscopy With a Robotic Endoscope, The CARE I Study

Acronym: CARE I

Important dates

Study start
2025
Primary completion
2025
Study completion
2025
First posted
Apr 20, 2025
Registry last updated
Apr 20, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.